CASES
BioMimetic Therapeutics, Inc.
Class Period: Oct 14, 2009 to May 11, 2011
Lead Plaintiff Deadline: Sep 6, 2011 + Deadline passed
Summary of Case:
A securities class action has been filed against BioMimetic Therapeutics, Inc. ("BMTI" or the "Company") on behalf of all persons or entities who purchased BioMimetic Therapeutics, Inc. ("BMTI" or the "Company") securities between October 14, 2009 to May 11, 2011. This case has been filed in the USDC - Tennessee (Middle).
The Complaint alleges as follows: Throughout the Class Period, defendants conditioned investors to believe that FDA approval of Augment would be forthcoming through a host of materially false and misleading statements regarding the status of Augment's ongoing clinical studies, and the safety and efficacy of the Company's product. Specifically, defendants made false and/or misleading statements and/or failed to disclose material facts regarding: (a) the Company's business, operations, management, future business prospects and the intrinsic value of BMTI's common stock; (b) the safety and efficacy of Augment and its prospects for FDA approval; and (c) the woeful inadequacies of Augment's clinical trials. As a result of the foregoing, the Company's statements were materially false and misleading at all relevant times.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.